@article{265356c1e7d641bda14c5e2b1404cd73,
title = "An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma",
abstract = "Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited understanding of brain metastasis tumor and immune biology, drivers of resistance to systemic treatment, and their overall poor prognosis. Current data support a multimodal treatment strategy with radiation treatment and/or surgery. Nonetheless, the optimal approach for the management of brain metastases from renal cell carcinoma remains unclear. To improve patient care, the authors sought to standardize practical management strategies. They performed an unstructured literature review and elaborated on the current management strategies through an international group of experts from different disciplines assembled via the network of the International Kidney Cancer Coalition. Experts from different disciplines were administered a survey to answer questions related to current challenges and unmet patient needs. On the basis of the integrated approach of literature review and survey study results, the authors built algorithms for the management of single and multiple brain metastases in patients with renal cell carcinoma. The literature review, consensus statements, and algorithms presented in this report can serve as a framework guiding treatment decisions for patients. CA Cancer J Clin. 2022;72:000-000.",
keywords = "brain metastases, diagnostic evaluation, immune checkpoint blockers, renal cell carcinoma",
author = "Elshad Hasanov and Yeboa, {Debra Nana} and Tucker, {Mathew D.} and Swanson, {Todd A.} and Beckham, {Thomas Hendrix} and Brian Rini and Ene, {Chibawanye I.} and Merve Hasanov and Sophie Derks and Marion Smits and Shaan Dudani and Heng, {Daniel Y.C.} and Brastianos, {Priscilla K.} and Axel Bex and Sahin Hanalioglu and Weinberg, {Jeffrey S.} and Laure Hirsch and Carlo, {Maria I.} and Ayal Aizer and Brown, {Paul David} and Bilen, {Mehmet Asim} and Chang, {Eric Lin} and Jerry Jaboin and James Brugarolas and Choueiri, {Toni K.} and Atkins, {Michael B.} and McGregor, {Bradley A.} and Halasz, {Lia M.} and Patel, {Toral R.} and Soltys, {Scott G.} and McDermott, {David F.} and Elder, {James Bradley} and Baskaya, {Mustafa K.} and Yu, {James B.} and Robert Timmerman and Kim, {Michelle Miran} and Melike Mut and James Markert and Kathryn Beal and Tannir, {Nizar M.} and George Samandouras and Lang, {Frederick F.} and Rachel Giles and Eric Jonasch",
note = "Funding Information: Elshad Hasanov reports research funding to his affiliated institution from the Conquer Cancer Foundation, the Kidney Cancer Association, and the International Kidney Cancer Coalition and honoraria from Targeted Oncology outside the submitted work. Brian Rini reports institutional research funding from Pfizer, Hoffman‐LaRoche, Incyte, AstraZeneca, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, Bristol‐Myers Squibb (BMS), Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis, and Janssen; consulting fees from BMS, Pfizer, Genentech/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GlaxoSmithKline, Shionogi, Eisai, and Nikang Therapeutics; and owns stock in PTC Therapeutics outside the submitted work. Sophie Derks reports personal fees from BMS outside the submitted work. Marian Smits reports speaking fees from GE Healthcare paid to her institution outside the submitted work. Pricilla K. Brastianos is supported by the Breast Cancer Research Foundation, the Damon Runyon Cancer Research Foundation, the Demetra Fund of the Hellenic Women{\textquoteright}s Association, the Ben and Catherine Ivy Foundation, and grants from the National Institutes of Health (5R01CA227156‐02, 1R21CA220253‐0A01, and 1R01CA244975‐01); reports personal fees from Angiochem, Genentech‐Roche, Eli Lilly & Company, Tesaro, ElevateBio, Pfizer, Sintetica, SK Life Sciences, and Dantari; institutional grant/research support from Merck, Mirati, BMS, and Eli Lilly & Company; and honoraria from Merck, Genentech‐Roche, Pfizer; and Eli Lilly & Company, all outside the submitted work. Axel Bex reports a restricted educational grant from Pfizer and participation on steering committees for clinical trials at Roche/Genentech and BMS outside the submitted work. Laure Hirsch reports research grant funding from AbbVie outside the submitted work. Paul David Brown reports honoraria from UpToDate outside the submitted work. Mehmet Asim Bilen reports institutional grants from Xencor, Bayer, BMS, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer; and personal fees from Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi outside the submitted work. James Brugarolas reports a research grant from Arrowhead and personal fees from Arrowhead, Calithera, Esai, Exelixis, and Johnson & Johnson outside the submitted work. Toni K. Choueiri is supported in part by the Dana‐Farber/Harvard Cancer Center Kidney Specialized Center of Research Excellence (SPORE; 2P50CA101942‐16) and Program 5P30CA006516‐56, the Kohlberg Chair at Harvard Medical School, and the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at the Dana Farber Cancer Institute; reports research/advisory boards/consultancy/honoraria (institutional and personal, paid and unpaid) from AstraZeneca, Aravive, Aveo, Bayer, BMS, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infiniti, Ipsen, Kanaph, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi/Aventis, Takeda, Tempest, and Up‐To‐Date; continuing medical education CME events for Peerview, OncLive, and others; and travel, accommodations, expenses, and medical writing in relation to consulting, advisory roles, or honoraria, all outside the submitted work. Bradley A. McGregor reports institutional research funding from BMS, Calithera, Exelixis, Pfizer, and Seattle Genetics; and service on advisory boards at Astellas, BMS, Calithera, Dendreon, Exelixis, Eisai, EMD Serono, Merck, Pfizer, and Seattle Genetics outside the submitted work. Scott G. Soltys reports research funding from Novocure; honoraria from Zap Surgical, Inc; and service on an advisory board at Accuray, Inc outside the submitted work. David F. McDermott reports institutional research funding from BMS, Merck, Genentech, Pfizer, Exelixis, X4 Pharma, and Alkermes; and honoraria for consulting from BMS, Merck, Pfizer, Alkermes, EMD Serono, Eli Lilly and Company, Iovance, Eisai Inc, Werewolf Therapeutics, and Calithera Biosciences outside the submitted work. James B. Yu reports consulting fees from Boston Scientific; service on an advisory board at Galera Pharmaceuticals; and speaking fees from RefleXion Medical outside the submitted work. The remaining authors report no conflicts of interest. DISCLOSURES: Publisher Copyright: {\textcopyright} 2022 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.",
year = "2022",
doi = "10.3322/caac.21729",
language = "English (US)",
journal = "CA Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
}